Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Invested Capital (2016 - 2025)

Historic Invested Capital for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $608.4 million.

  • Arrowhead Pharmaceuticals' Invested Capital rose 95445.75% to $608.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $608.4 million, marking a year-over-year increase of 95445.75%. This contributed to the annual value of $543.4 million for FY2025, which is 18441.72% up from last year.
  • Arrowhead Pharmaceuticals' Invested Capital amounted to $608.4 million in Q4 2025, which was up 95445.75% from $543.4 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Invested Capital's 5-year high stood at $749.2 million during Q1 2025, with a 5-year trough of $57.7 million in Q4 2024.
  • Moreover, its 5-year median value for Invested Capital was $427.6 million (2021), whereas its average is $413.0 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Invested Capital crashed by 6678.45% in 2024 and then skyrocketed by 95445.75% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Invested Capital stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then plummeted by 56.17% to $173.7 million in 2023, then tumbled by 66.78% to $57.7 million in 2024, then soared by 954.46% to $608.4 million in 2025.
  • Its last three reported values are $608.4 million in Q4 2025, $543.4 million for Q3 2025, and $562.3 million during Q2 2025.